Roivant reports Phase 3 thyroid eye disease data, launches new hair loss trial, holds $4.3B cash

Filed April 2, 2026 · Period ending April 2, 2026 · ~1 min read

Key Changes

• high

  Immunovant reported topline Phase 3 results for batoclimab in thyroid eye disease, a pivotal readout that will determine whether the drug can advance to regulatory approval. Specific efficacy outcomes were not disclosed in the 8-K.

  Item 8.01 Press Release view on EDGAR →
• high

  Roivant held approximately $4.3 billion in cash, cash equivalents, and marketable securities as of March 31, 2026 (preliminary, unaudited). This strong balance sheet supports ongoing clinical programs and business development.

  Item 8.01 Cash Position view on EDGAR →
• medium

  Priovant initiated a Phase 2b/3 trial of brepocitinib for lichen planopilaris, a scarring hair loss condition. This expands the drug's potential indications beyond existing programs.

  Item 8.01 Press Release view on EDGAR →